Autoimmune Diabetes Clinical Trial
Official title:
Autoimmune Diabetes: Disease Markers and Treatment of Latent Autoimmune Diabetes in Adults (LADA)
Autoimmunity is the main cause of diabetes type 1 and an important factor as cause of Latent
Autoimmune Diabetes in Adults (LADA). Recently, research has found that being deficient of
T-reg cells is an important cause of autoimmunity. The study hypothesis are:
1. Patients with newly found diabetes type 1 have less T-reg than healthy.
2. Patients with newly found diabetes type 1 have less T-reg than patients with long
duration of the illness.
3. The number of T-reg is negative associated with HLA-risk-haplotype.
4. The number of T-reg is negative associated with LADA.
5. Differences relating to inflammatory cytokines will be seen among patients with newly
found diabetes type 1, but not among others.
Research has worked out that b-cells are being destroyed by cytokines released from
inflammatory cells. One hypothesis in that T-reg is a cause of autoimmunity, and that T-reg
concentrations are low in patients with newly diagnosed diabetes type 1.
Blood samples will be taken from 10 patients with newly diagnosed type 1 diabetes, Latent
Autoimmune Diabetes in Adults (LADA) and type 1 diabetes older than 10 years and the same
amount of samples from healthy, age- and sex-matched blood donors. Markers of autoimmune
diabetes will be analyzed.
;
Observational Model: Cohort, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03618420 -
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05866536 -
Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years
|
Phase 2 | |
| Not yet recruiting |
NCT04698330 -
Effects Of Berberine Plus Inulin On Diabetes Care in Patients With LADA
|
Phase 4 | |
| Recruiting |
NCT05319990 -
Pathogenesis of Kidney Disease in Type 1 Diabetes: a Modern Kidney Biopsy Cohort (The PANDA Study)
|
||
| Completed |
NCT04793165 -
Is the Artificial Pancreas, Without Carbohydrate Counting, Efficient and Safe in an Outpatient Setting
|
N/A | |
| Completed |
NCT05168657 -
Feasibility of Closed-loop Automated Insulin Delivery System by Primary Care & Endocrinology, in Person & Via Telehealth
|
N/A | |
| Recruiting |
NCT05180591 -
Repeat BCG Vaccinations For The Treatment Of Pediatric Type 1 Diabetes
|
Phase 2 | |
| Recruiting |
NCT01559025 -
Evaluation of Vildagliptin (Galvus®) as add-on to Insulin in New-onset Type 1 Diabetes Mellitus
|
Phase 3 | |
| Not yet recruiting |
NCT04902807 -
Conception of a Diagnosis, Prognosis and Therapeutic Decision Tool for Patients With Autoimmunity and Inflammation
|
||
| Active, not recruiting |
NCT02081326 -
Repeat BCG Vaccinations for the Treatment of Established Type 1 Diabetes
|
Phase 2 | |
| Completed |
NCT01881009 -
Medtronic Minimed Overnight Closed-Loop System
|
N/A | |
| Recruiting |
NCT03011008 -
Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus
|
Phase 4 | |
| Recruiting |
NCT03011021 -
Safety and Efficacy of Umbilical Cord Blood Regulatory T Cells Plus Liraglutide on Autoimmune Diabetes
|
Phase 1/Phase 2 | |
| Completed |
NCT04074668 -
Control of Renal Oxygen Consumption, Mitochondrial Dysfunction, and Insulin Resistance
|
||
| Terminated |
NCT00837759 -
Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes
|
Phase 2 | |
| Completed |
NCT03345004 -
Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes
|
Phase 2 | |
| Active, not recruiting |
NCT03945747 -
MEtabolic and Renal Effects of AutoMAted Insulin Delivery Systems in Youth With Type 1 Diabetes Mellitus
|
||
| Recruiting |
NCT03513874 -
Metformin Plus Insulin on Non-obese Autoimmune Diabetes
|
Phase 4 | |
| Enrolling by invitation |
NCT04335513 -
Trial of Early Initiation of CGM-Guided Insulin Therapy in Stage 2 T1D
|
N/A |